Haynes DR et al. |
Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. |
2001 |
Rheumatology (Oxford) |
pmid:11426018
|
Szulc P et al. |
Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. |
2001 |
J. Clin. Endocrinol. Metab. |
pmid:11443182
|
Sakiyama H et al. |
Establishment and characterization of macrophage-like cell lines expressing osteoclast-specific markers. |
2001 |
J. Bone Miner. Metab. |
pmid:11448014
|
Choi Y et al. |
Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. |
2001 |
Eur. J. Immunol. |
pmid:11449372
|
Kanzaki H et al. |
Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. |
2001 |
J. Dent. Res. |
pmid:11379890
|
Hein GE |
[Pathophysiology of bone loss in rheumatic diseases--do bone markers help in monitoring?]. |
2001 |
Z Rheumatol |
pmid:11383046
|
Morony S et al. |
Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. |
2001 |
Cancer Res. |
pmid:11389072
|
Kim KJ et al. |
Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty. |
2001 |
J. Biomed. Mater. Res. |
pmid:11410897
|
Abu-Amer Y |
IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. |
2001 |
J. Clin. Invest. |
pmid:11390419
|
Kon T et al. |
Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. |
2001 |
J. Bone Miner. Res. |
pmid:11393777
|
Fazzalari NL et al. |
The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. |
2001 |
J. Bone Miner. Res. |
pmid:11393778
|
Bekker PJ et al. |
The effect of a single dose of osteoprotegerin in postmenopausal women. |
2001 |
J. Bone Miner. Res. |
pmid:11204435
|
Kikuchi T et al. |
Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. |
2001 |
J. Immunol. |
pmid:11207318
|
O'Brien EA et al. |
Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. |
2001 |
Bone |
pmid:11182380
|
Goltzman D |
Osteolysis and cancer. |
2001 |
J. Clin. Invest. |
pmid:11375409
|
Stejskal D et al. |
Osteoprotegerin, RANK, RANKL. |
2001 |
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub |
pmid:12426773
|
Stejskal D et al. |
Osteoprotegerin and bone density. |
2001 |
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub |
pmid:12426776
|
Sasaki N et al. |
Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. |
2001 |
Nephrol. Dial. Transplant. |
pmid:11239019
|
Takeuchi T et al. |
Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. |
2001 |
Biochem. Pharmacol. |
pmid:11239501
|
Mori K et al. |
Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. |
2001 |
Cell. Immunol. |
pmid:11243701
|
Hofbauer LC et al. |
Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. |
2001 |
Biochem. Biophys. Res. Commun. |
pmid:11162519
|
Brändström H et al. |
Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. |
2001 |
Biochem. Biophys. Res. Commun. |
pmid:11162596
|
Wuyts W et al. |
Evaluation of the role of RANK and OPG genes in Paget's disease of bone. |
2001 |
Bone |
pmid:11165949
|
Michigami T et al. |
Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. |
2001 |
Cancer Res. |
pmid:11245477
|
Wada N et al. |
Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. |
2001 |
J. Periodont. Res. |
pmid:11246705
|
Jung K et al. |
Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. |
2001 |
Clin. Chem. |
pmid:11673385
|
Lean JM et al. |
FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. |
2001 |
Blood |
pmid:11675341
|
Fiumara P et al. |
Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. |
2001 |
Blood |
pmid:11675352
|
Satoh K et al. |
Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. |
2001 |
Pancreas |
pmid:11590320
|
Yano K et al. |
Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy. |
2001 |
Biochem. Biophys. Res. Commun. |
pmid:11594776
|
Brown JM et al. |
Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. |
2001 |
Clin. Cancer Res. |
pmid:11595685
|
Price PA et al. |
Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. |
2001 |
Arterioscler. Thromb. Vasc. Biol. |
pmid:11597934
|
Nemec K and Schubert-Zsilavecz M |
[Future therapies for metabolic bone diseases. New concepts and targets]. |
2001 |
Pharm Unserer Zeit |
pmid:11715689
|
Kuntz KA et al. |
An immunohistochemical study of osteoprotegerin in the human dental pulp. |
2001 |
J Endod |
pmid:11716077
|
Hofbauer LC and Schoppet M |
Serum measurement of osteoprotegerin--clinical relevance and potential applications. |
2001 |
Eur. J. Endocrinol. |
pmid:11720890
|
Ueland T et al. |
Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. |
2001 |
Eur. J. Endocrinol. |
pmid:11720891
|
Pearse RN et al. |
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. |
2001 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:11562486
|
Kostenuik PJ et al. |
OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. |
2001 |
Endocrinology |
pmid:11564687
|
Marco-Mingot M et al. |
Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. |
2001 |
Clin. Genet. |
pmid:11531977
|
Raffai RL et al. |
Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. |
2001 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:11553788
|
Hocking LJ et al. |
Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. |
2001 |
Am. J. Hum. Genet. |
pmid:11555792
|
Hofbauer LC et al. |
Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. |
2001 |
Cancer |
pmid:11505389
|
Hofbauer LC and Heufelder AE |
Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. |
2001 |
J. Mol. Med. |
pmid:11485016
|
Furuya D et al. |
Immuno-PCR assay for homodimeric osteoprotegerin. |
2001 |
Clin. Chem. |
pmid:11468243
|
Seck T et al. |
Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. |
2001 |
Eur. J. Endocrinol. |
pmid:11454517
|
Burguera B et al. |
Leptin reduces ovariectomy-induced bone loss in rats. |
2001 |
Endocrinology |
pmid:11459801
|
Yamagishi T et al. |
Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. |
2001 |
Endocrinology |
pmid:11459812
|
Ma YL et al. |
Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. |
2001 |
Endocrinology |
pmid:11517184
|
Bateman TA et al. |
Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. |
2001 |
J. Orthop. Res. |
pmid:11518255
|
Myoung H et al. |
Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. |
2001 |
J. Periodont. Res. |
pmid:11519698
|
Haynes DR et al. |
The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. |
2001 |
J Bone Joint Surg Br |
pmid:11521937
|
Hofbauer LC and Schoppet M |
Osteoprotegerin: a link between osteoporosis and arterial calcification? |
2001 |
Lancet |
pmid:11498208
|
Sakai A et al. |
1alpha-Hydroxyvitamin D3 suppresses trabecular bone resorption by inhibiting osteoclastogenic potential in bone marrow cells after ovariectomy in mice. |
2001 |
J. Bone Miner. Metab. |
pmid:11498729
|
Ikeda T et al. |
Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. |
2001 |
J. Bone Miner. Res. |
pmid:11499864
|
Thomas GP et al. |
Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. |
2001 |
J. Endocrinol. |
pmid:11479141
|
Allan GF et al. |
Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification. |
2001 |
Steroids |
pmid:11546554
|
Halladay DL et al. |
Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. |
2001 |
J. Cell. Biochem. |
pmid:11746511
|
Cao Y et al. |
IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. |
2001 |
Cell |
pmid:11747812
|
Chung H et al. |
Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. |
2001 |
J. Korean Med. Sci. |
pmid:11748360
|
Komuro H et al. |
The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. |
2001 |
Arthritis Rheum. |
pmid:11762937
|
Lindberg MK et al. |
Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. |
2001 |
J. Endocrinol. |
pmid:11739008
|
Giuliani N et al. |
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. |
2001 |
Blood |
pmid:11739153
|
Croucher PI et al. |
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. |
2001 |
Blood |
pmid:11739154
|
Dhore CR et al. |
Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. |
2001 |
Arterioscler. Thromb. Vasc. Biol. |
pmid:11742876
|
Ramalho AC et al. |
Effect of oestradiol on cytokine production in immortalized human marrow stromal cell lines. |
2001 |
Cytokine |
pmid:11792122
|
Fukagawa M et al. |
[PTH and bone metabolism in chronic dialysis patients]. |
2001 |
Rinsho Byori |
pmid:11307321
|
Horowitz MC et al. |
Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. |
2001 |
Cytokine Growth Factor Rev. |
pmid:11312114
|
Lin DL et al. |
Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. |
2001 |
Prostate |
pmid:11351351
|
Sparks AB et al. |
Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. |
2001 |
Calcif. Tissue Int. |
pmid:11351498
|
Yan T et al. |
Regulation of osteoclastogenesis and RANK expression by TGF-beta1. |
2001 Aug 1-9 |
J. Cell. Biochem. |
pmid:11573248
|
Rosa-Rañal M et al. |
[New paradigms in the regulation of bone metabolism]. |
2001 Jul-Aug |
Rev. Invest. Clin. |
pmid:11599485
|
Ziolkowska M et al. |
High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. |
2002 |
Arthritis Rheum. |
pmid:12124857
|
Campagnuolo G et al. |
Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. |
2002 |
Arthritis Rheum. |
pmid:12124878
|
Sakata M et al. |
Osteoprotegerin levels increased by interleukin-1beta in human periodontal ligament cells are suppressed through prostaglandin E(2) synthesized de novo. |
2002 |
Cytokine |
pmid:12126649
|
Petersson M et al. |
Oxytocin stimulates proliferation of human osteoblast-like cells. |
2002 |
Peptides |
pmid:12126740
|
Cundy T et al. |
A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. |
2002 |
Hum. Mol. Genet. |
pmid:12189164
|
Khosla S et al. |
Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. |
2002 |
J. Clin. Endocrinol. Metab. |
pmid:11932280
|
Kanematsu M et al. |
Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway. |
2002 |
Bone |
pmid:11934645
|
Li X et al. |
Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. |
2002 |
Bone |
pmid:11934647
|
Jiang Y et al. |
Bacteria induce osteoclastogenesis via an osteoblast-independent pathway. |
2002 |
Infect. Immun. |
pmid:12011008
|
Granchi D et al. |
Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells. |
2002 |
Biomaterials |
pmid:12013183
|
Palenzuela L et al. |
Familial expansile osteolysis in a large Spanish kindred resulting from an insertion mutation in the TNFRSF11A gene. |
2002 |
J. Med. Genet. |
pmid:12362049
|
Fu Q et al. |
Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. |
2002 |
J. Biol. Chem. |
pmid:12364326
|
Rogers A et al. |
Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. |
2002 |
J. Clin. Endocrinol. Metab. |
pmid:12364420
|
Zhao S et al. |
MLO-Y4 osteocyte-like cells support osteoclast formation and activation. |
2002 |
J. Bone Miner. Res. |
pmid:12412815
|
Hu Y and Yu S |
Gene expression of osteoprotegerin and osteoclast differentiation factor in giant cell tumor. |
2002 |
Zhonghua Bing Li Xue Za Zhi |
pmid:12419159
|
Sandor M et al. |
A novel polyethylene depot device for the study of PLGA and P(FASA) microspheres in vitro and in vivo. |
2002 |
Biomaterials |
pmid:12219832
|
Shiotani A et al. |
Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. |
2002 |
Anat. Rec. |
pmid:12221720
|
Cremer I et al. |
Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. |
2002 |
Blood |
pmid:12393586
|
Theill LE et al. |
RANK-L and RANK: T cells, bone loss, and mammalian evolution. |
2002 |
Annu. Rev. Immunol. |
pmid:11861618
|
Roux S et al. |
RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. |
2002 |
Am. J. Clin. Pathol. |
pmid:11863217
|
Green EA et al. |
Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. |
2002 |
Immunity |
pmid:11869680
|
Holen I et al. |
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. |
2002 |
Cancer Res. |
pmid:11912131
|
Buckley KA and Fraser WD |
Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. |
2002 |
Ann. Clin. Biochem. |
pmid:12564836
|
Holloway WR et al. |
Leptin inhibits osteoclast generation. |
2002 |
J. Bone Miner. Res. |
pmid:11811550
|
Coen G et al. |
Serum osteoprotegerin and renal osteodystrophy. |
2002 |
Nephrol. Dial. Transplant. |
pmid:11812872
|
Bolon B et al. |
Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. |
2002 |
Cell. Mol. Life Sci. |
pmid:12440777
|
David JP et al. |
JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. |
2002 |
J. Cell. Sci. |
pmid:12376563
|
Jones DH et al. |
Role of RANKL and RANK in bone loss and arthritis. |
2002 |
Ann. Rheum. Dis. |
pmid:12379618
|
Gravallese EM |
Bone destruction in arthritis. |
2002 |
Ann. Rheum. Dis. |
pmid:12379632
|